2023年，第59届美国临床肿瘤学会（ASCO）年会将于美国芝加哥当地时间6月2日至6日举行。4月26日，ASCO官网已公布了本次会议的日程和摘要题目。本期【肿瘤资讯】整理了2023 ASCO年会口头报告（Oral Abstract Session）专场的肺癌重磅研究，与读者分享。
局部-区域非小细胞肺癌/小细胞肺癌/其他胸部肿瘤
专场时间：2023年6月4日04:00（北京时间）
专场主席：Mauricio Burotto、Vamsidhar Velcheti
摘要号：8500
Surgical outcomes of patients with resectable non-small-cell lung cancer receiving neoadjuvant immunotherapy with nivolumab plus relatlimab or nivolumab: Findings from the prospective, randomized, multicentric phase II study NEOpredict-Lung.
前瞻性、随机、多中心II期研究NEOpredict-Lung：可切除非小细胞肺癌患者接受纳武利尤单抗联合relatlimab或纳武利尤单抗新辅助免疫治疗的手术结果
讲者:Clemens Aigner, MD, MBA | West German Cancer Center, University Medicine Essen - Ruhrlandklinik
摘要号：8501
Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study.
可切除的Ⅱ/Ⅲ期非小细胞肺癌围手术期特瑞普利单抗+双铂化疗与化疗的比较：Ⅲ期NEOTORCH研究的无事件生存（EFS）分析
讲者:陆舜, PhD | Shanghai Chest Hospital, Jiao Tong University
摘要号：8502
First-in-human dose-escalation trial of the delta-like ligand 3 (DLL3)/CD3 bispecific T-cell engager BI 764532 in patients (pts) with DLL3-positive (DLL3+) small-cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC)
在DLL 3阳性（DLL 3+）小细胞肺癌（SCLC）和神经内分泌癌（NEC）患者中开展的δ样配体3（DLL 3）/CD 3双特异性T细胞衔接子BI 764532的首次人体剂量递增试验
讲者：Martin Wermke, MD | Technical University Dresden, NCT/UCC Early Clinical Trial Unit
摘要号：8503
Exploratory biomarker analysis of the phase 3 KEYNOTE-604 study of pembrolizumab plus etoposide for extensive-stage SCLC.
帕博利珠单抗联合依托泊苷治疗广泛期SCLC的KEYNOTE-604 3期研究的探索性生物标志物分析
讲者：Charles M. Rudin, MD, PhD | Memorial Sloan Kettering Cancer Center
摘要号：8504
SWOG S1929: Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer (ES-SCLC).
SWOG S1929：在SLFN 11阳性广泛期小细胞肺癌（ES-SCLC）患者中比较阿替利珠单抗（A）与阿替利珠单抗 +他拉唑帕利（AT）维持治疗的II期随机研究
讲者：Nagla Fawzy Abdel Karim, MD | Inova Schar Cancer Institute, University of Virginia
摘要号：LBA8505
IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (Pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial.
在恶性胸膜间皮瘤（PM）患者中评价顺铂/培美曲塞（CP）联合或不联合帕博利珠单抗的LBA 8505 IND 227 III期（P3）研究：CCTG、NCIN和IFCT试验
讲者：Quincy S. Chu, MD | Cross Cancer Institute
摘要号：8506
Efficacy, cellular and molecular determinants of PD-1 checkpoint inhibition in relapsed mesothelioma.
复发性间皮瘤中PD-1检查点抑制的功效、细胞和分子决定因素
讲者：Dean Anthony Fennell, PhD, FRCP | University of Leicester and Leicester University Hospitals
摘要号：8506
Association of somatic mutations and histologic subtype/grade on prognosis and PD-L1 expression in mesothelioma
间皮瘤体细胞突变和组织学亚型/分级与预后和PD-L1表达的相关性
讲者：Allen Chengzhi Zhu, PhD | University of Chicago
晚期非小细胞肺癌
专场时间：2023年6月6日22:45（北京时间）
专场主席：Clarissa Mathias、Heather Wakelee
摘要：LBA9000
Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.
KEYNOTE-789 3期研究：培美曲塞+铂类±帕博利珠单抗治疗TKI耐药EGFR突变晚期非鳞状NSCLC
讲者：James Chih-Hsin Yang, MD, PhD | National Taiwan University Hospital and National Taiwan University Cancer Center
摘要：9001
Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis.
AZD3759（zorifertinib）对比吉非替尼或厄洛替尼一线治疗中枢神经系统转移EGFR突变NSCLC的III期随机研究
讲者：吴一龙, FACS | Guangdong Lung Cancer Institute
摘要：9002
Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results.
舒沃替尼治疗EGFR 20号外显子插入突变晚期NSCLC：第一个关键研究结果
讲者：王孟昭, MD | Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
摘要：9003
Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations.
CHOICE-01研究最终生存和生物标志物分析：比较特瑞普利单抗+化疗与安慰剂+化疗治疗无EGFR/ALK晚期NSCLC的双盲、随机、III期临床试验
讲者：邬麟, PhD | Hunan Cancer Hospital
摘要：9004
9004 TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC).
TROPION-Lung02：Datopotamab deruxtecan（Dato-DXd）联合帕博利珠单抗联合或不联合铂类化疗治疗晚期非小细胞肺癌
讲者：Yasushi Goto, MD | National Cancer Center Hospital
摘要：LBA 9005
Tumor Treating Field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: Randomized, phase 3 LUNAR study.
LUNAR随机、III期研究：电场疗法（TTFields）联合标准治疗用于含铂化疗失败的晚期非小细胞肺癌
讲者：Ticiana Leal, MD | Winship Cancer Institute of Emory University
摘要：9006
The primary endpoint analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in patients with advanced non-squamous, non-small cell lung cancer with KRAS G12C mutation (WJOG14821L).
SCARLET研究主要终点分析：一项II期研究，sotorasib+卡铂+培美曲塞治疗伴KRAS G12 C突变的晚期非鳞状非小细胞肺（WJOG 14821 L）
讲者：Hiroaki Akamatsu, MD, PhD | Internal Medicine III, Wakayama Medical University
摘要：9007
KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC).
KontRASt-01研究更新：JDQ 443在KRAS G12 C突变的实体瘤（包括非小细胞肺癌）中的疗效和安全性
讲者：Philippe Alexandre Cassier, MD, PhD | Centre Léon Bérard
摘要：9008
Biomarker subgroup analyses of CodeBreaK 200, a phase 3 trial of sotorasib versus (vs) docetaxel in patients (pts) with pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC).
CodeBreaK 200研究的生物标志物分析：sotorasib对比多西他赛用于经治KRAS G12C突变晚期非小细胞肺癌的III期研究
讲者：Ferdinandos Skoulidis, PhD | University of Texas MD Anderson Cancer Center
本文依照报告日期和出场排序整理，如有错误或遗漏，敬请留言指正。
参考文献
https://meetings.asco.org/meetings/2023-asco-annual-meeting/299/program-guide/scheduled-sessions
排版编辑：肿瘤资讯-CY
苏公网安备32059002004080号
